CAESAREA, Israel, November 7, 2011 /PRNewswire/ --
Angioslide, a provider of Embolic Capture Angioplasty solutions, announced today that it has been named one of Israel's top ten most promising startups of 2011. The award was presented to Angioslide during the Ernst & Young (E&Y) Journey 2011 conference, held in Tel Aviv - one of Israel's leading technology conferences, featuring prominent technology, healthcare and cleantech companies.
"We are proud and honored to receive this award," said Lihu Avitov, CEO of Angioslide. "Angioslide's innovative technology enables physicians to perform intravascular interventions while simultaneously providing embolic protection without the use of additional devices. We have an early and growing group of physicians who are integrating our products into their standard of care for treating difficult lesions in peripheral vascular disease. We are focused on providing our clients with a full range of products and expanding adoption of our products around the world."
"The Angioslide PROTEUS™ catheter is a unique and proprietary device that combines balloon angioplasty and embolic capture, "said Mike Berman, a board member of Angioslide. "Physicians are increasingly recognizing the potential of the PROTEUS to treat complex peripheral vascular disease."
Over 18 million people suffer from peripheral artery disease in the US alone. In recent years catheter-based interventions have become the primary therapeutic approach for these patients. With the increase in life expectancy, diabetes prevalence, and number of high-risk patients, physicians are seeking to expand the current interventional "tool box" to improve procedure outcomes. Angioslide's PROTEUS device, combining a Percutaneous Transluminal Angioplasty (PTA) balloon and embolic capture of particles in one device, addresses this need.
Founded in 2005, Angioslide is a privately held medical device company that developed a unique Embolic Capture Angioplasty solution, PROTEUS™, which provides a combination of PTA balloon and embolic capture. The PROTEUS device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic particle capture solution for the peripheral vascular disease market. It is the first device of its kind to receive FDA clearance for use in lower limbs. The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, with regional offices in Europe and the US. For more information visit our website at http://www.angioslide.com
|SOURCE Angioslide Ltd.|
Copyright©2010 PR Newswire.
All rights reserved